LC
SLRN

Lindbrook Capital’s ACELYRIN SLRN Stock Holding History

Lindbrook Capital’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-170
Closed -$1.15K – 2829
2024
Q1 		$1.15K Hold
170
– – ﹤0.01% 2387
2023
Q4 		$1.27K Sell
170
-146
-46% -$1.25K ﹤0.01% 2411
2023
Q3 		$3.21K Buy
+316
New +$6.71K ﹤0.01% 1956

Other funds holding SLRN

ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Lindbrook Capital's SLRN Position: Q2 2024 in Review

Lindbrook Capital sold out of ACELYRIN (SLRN) in Q2 2024, closing a stake of 170 shares — an estimated $1.15K sold.

Lindbrook Capital first reported a position in SLRN in Q3 2023 and held it in 3 quarters. The position peaked at $3.21K in Q3 2023. 112 funds tracked by Wall St. Rank hold SLRN as of Q2 2024.

  • Lindbrook Capital reported no remaining ACELYRIN position as of Q2 2024 after selling out during the quarter.
  • Lindbrook Capital sold 170 ACELYRIN shares in Q2 2024, an estimated $1.15K.
  • Lindbrook Capital first reported a position in ACELYRIN in Q3 2023 and held it in 3 quarters.
  • Lindbrook Capital's ACELYRIN position peaked at $3.21K in Q3 2023.
  • 112 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2024.

Based on Lindbrook Capital's 13F filing for Q2 2024, filed 31 Jul 2024.